Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Plasmodium falciparum is the major cause of malaria globally and is transmitted by mosquitoes. During parasitic development, P. falciparum-infected erythrocytes (P. falciparum-IEs) express multiple polymorphic proteins known as variant surface antigens (VSAs), including the P. falciparum erythrocyte membrane protein 1 (PfEMP1). VSA-specific antibodies are associated with protection from symptomatic and severe malaria. However, the importance of the different VSA targets of immunity to malaria remains unclear, which has impeded an understanding of malaria immunity and vaccine development. In this study, we developed assays using transgenic P. falciparum with modified PfEMP1 expression to quantify serum antibodies to VSAs among individuals exposed to malaria. We found that the majority of the human antibody response to the IE targets PfEMP1. Furthermore, our longitudinal studies showed that individuals with PfEMP1-specific antibodies had a significantly reduced risk of developing symptomatic malaria, whereas antibodies to other surface antigens were not associated with protective immunity. Using assays that measure antibody-mediated phagocytosis of IEs, an important mechanism in parasite clearance, we identified PfEMP1 as the major target of these functional antibodies. Taken together, these data demonstrate that PfEMP1 is a key target of humoral immunity. These findings advance our understanding of the targets and mediators of human immunity to malaria and have major implications for malaria vaccine development.

Original publication

DOI

10.1172/JCI62182

Type

Journal article

Journal

J Clin Invest

Publication Date

09/2012

Volume

122

Pages

3227 - 3238

Keywords

Adolescent, Adult, Antibodies, Protozoan, Antigens, Protozoan, Child, Child, Preschool, Disease Resistance, Disease-Free Survival, Endemic Diseases, Erythrocytes, Genetic Engineering, Humans, Infant, Kaplan-Meier Estimate, Kenya, Malaria, Falciparum, Middle Aged, Organisms, Genetically Modified, Phagocytosis, Plasmodium falciparum, Promoter Regions, Genetic, Protozoan Proteins, Statistics, Nonparametric, Young Adult